Overview

* XOMA reports Q3 net income of $14.1 mln, reversing last year's net loss

* Company received $14.3 mln in royalties during Q3, totaling $43.9 mln year-to-date

Outlook

* Company anticipates several clinical readouts that could impact business trajectory

* Company did not provide specific financial guidance for future quarters

Result Drivers

* ROYALTY INTERESTS - Secured royalty interests in partnered assets through acquisition of LAVA Therapeutics

* R&D expenses for the three and nine months ended September 30, 2025, were $69 thousand and $1.4 million, respectively, compared with $0.8 million and $2.0 million for each of the corresponding periods of 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS $0.70

Q3 Net $14.10

Income mln

Q3 $10.68

Operatin mln

g

Expenses

Q3 -$1.33

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the entertainment production peer group is "buy"

* Wall Street's median 12-month price target for Xoma Royalty Corp ( XOMA ) is $55.00, about 37.3% above its November 11 closing price of $34.49

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)